Compare ASTRAZENECA PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs WOCKHARDT - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA WOCKHARDT ASTRAZENECA PHARMA/
WOCKHARDT
 
P/E (TTM) x 81.4 -19.5 - View Chart
P/BV x 22.9 1.0 2,234.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   WOCKHARDT
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
WOCKHARDT
Mar-18
ASTRAZENECA PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,2781,012 126.3%   
Low Rs883532 166.1%   
Sales per share (Unadj.) Rs228.4355.9 64.2%  
Earnings per share (Unadj.) Rs10.4-60.3 -17.2%  
Cash flow per share (Unadj.) Rs16.3-46.8 -34.8%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs98.8257.8 38.3%  
Shares outstanding (eoy) m25.00110.63 22.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.2 218.1%   
Avg P/E ratio x104.2-12.8 -814.1%  
P/CF ratio (eoy) x66.4-16.5 -402.6%  
Price / Book Value ratio x10.93.0 365.4%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m27,00885,379 31.6%   
No. of employees `0001.46.3 21.7%   
Total wages/salary Rs m1,5359,371 16.4%   
Avg. sales/employee Rs Th4,210.96,295.0 66.9%   
Avg. wages/employee Rs Th1,132.21,498.3 75.6%   
Avg. net profit/employee Rs Th191.1-1,066.3 -17.9%   
INCOME DATA
Net Sales Rs m5,71039,369 14.5%  
Other income Rs m1231,202 10.2%   
Total revenues Rs m5,83340,571 14.4%   
Gross profit Rs m46318 2,529.5%  
Depreciation Rs m1471,495 9.9%   
Interest Rs m02,555 0.0%   
Profit before tax Rs m438-2,830 -15.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m179257 69.6%   
Profit after tax Rs m259-6,669 -3.9%  
Gross profit margin %8.10 17,440.3%  
Effective tax rate %40.8-9.1 -449.7%   
Net profit margin %4.5-16.9 -26.8%  
BALANCE SHEET DATA
Current assets Rs m3,20933,796 9.5%   
Current liabilities Rs m2,07026,917 7.7%   
Net working cap to sales %20.017.5 114.2%  
Current ratio x1.61.3 123.5%  
Inventory Days Days7279 91.2%  
Debtors Days Days3589 39.1%  
Net fixed assets Rs m79039,664 2.0%   
Share capital Rs m50553 9.0%   
"Free" reserves Rs m2,41927,968 8.7%   
Net worth Rs m2,46928,522 8.7%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m4,60581,620 5.6%  
Interest coverage xNM-0.1-  
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.20.5 257.0%   
Return on assets %5.6-5.0 -111.6%  
Return on equity %10.5-23.4 -44.9%  
Return on capital %17.7-7.7 -231.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3009,807 3.1%   
Fx outflow Rs m2,0151,789 112.7%   
Net fx Rs m-1,7158,019 -21.4%   
CASH FLOW
From Operations Rs m88684 12.8%  
From Investments Rs m-946,302 -1.5%  
From Financial Activity Rs mNA-7,695 0.0%  
Net Cashflow Rs m-6-664 0.9%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.3 13.0%  
FIIs % 15.7 7.7 203.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 67,757 19.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  AUROBINDO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 246 Points Higher; Capital Goods and Power Stocks Witness Buying(Closing)

Extending gains to the sixth day, Indian share markets traded on a positive note most of the day and ended higher.

Related Views on News

WOCKHARDT Surges by 5%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Oct 18, 2019 | Updated on Oct 18, 2019

WOCKHARDT share price has surged by 5% and its current market price is Rs 273. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.3%) and JUBILANT LIFE SCIENCES (up 5.2%). The top losers are GSK PHARMA (down 0.1%) and PROCTER & GAMBLE HEALTH (down 0.2%).

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 18, 2019 03:37 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - NOVARTIS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS